Hidroxicloroquina y azitromicina: riesgo cardiovascular, prolongación de QTc y muerte súbita en el nuevo escenario de la pandemia por COVID-19

Luis D. Barja, Mario Fitz Maurice, Elibet Chávez González

Texto completo:

HTML PDF PDF (English)

Resumen

Hidroxicloroquina y azitromicina: riesgo cardiovascular, prolongación de QTc y muerte súbita en el nuevo escenario de la pandemia por COVID-19

Referencias

Ministerios de Sanidad. Documento técnico: Manejo clínico del COVID-19: tratamiento médico [Internet]. Madrid: Gobierno de España [citado 19 Mar 2020]; 2020. Disponible en: http://www.aeemt.com/web/wp-content/uploads/2020/03/4_6026300193912129107.pdf

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol [Internet]. 2020 [citado 19 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.jacc.2020.03.031

Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol. 2013;19(5):286-8.

Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5.

Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc [Internet]. 2020 [citado 20 Mar 2020];95: En Prensa. Disponible en: https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_covid19.pdf

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care [Internet]. 2020 [citado 19 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.jcrc.2020.03.005

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722-7.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 [citado 20 Mar 2020]: En Prensa. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949

CredibleMeds.COVID-19 experimental therapies and TdP Risk [Internet]. En Línea 20 Marzo 2020 [citado 20 Mar 20]. Disponible en: https://crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk/

Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int [Internet]. 2018 [citado 20 Mar 2020];2018:1574806. En Prensa. Disponible en: https://doi.org/10.1155/2018/1574806

Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631-40.

Howard PA. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother. 2013;47(11):1547-51.

Galán Martínez L, Calderín Pulido AD, Fleites-Vázquez A. Acción inotrópico negativa y prolongación del intervalo QT por azitromicina. Rev Cuban Cardiol [Internet]. 2017 [citado 20 Mar 2020];23(4). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/720/pdf_108

Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol [Internet]. 2017 [citado 20 Mar 2020];10(4):e003560. Disponible en:https://doi.org/10.1161/CIRCEP.115.003560

Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, et al. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. Cardiovasc Toxicol. 2017;17(4):434-40.

Miranda-Aquino T, Pérez-Topete SE, Ortega-Pantoja W, Gómez-Vázquez CA, Meneses-Pérez LG, González-Padilla C, et al. Síndrome de QT largo secundario a la interacción entre hidroxicloroquina y amiodarona. Rev Mex Cardiol. 2018;29(2):98-101.

Taira CA, Opezzo JA, Mayer MA, Höcht C. Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf. 2010;5(1):65-72.

CredibleMeds. Risk Categories for Drugs that Prolong QT & induce Torsades de Pointes (TdP) [Internet]. Última revisión 19 Marzo 2020 [citado 20 Mar 2020]. Disponible en: https://crediblemeds.org/new-drug-list/

Enlaces refback

  • No hay ningún enlace refback.